Clinical trial

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

NCT04015622

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2020-10-07

PhasePHASE2

Study timeline

Study start (actual)2020-10-07Date precision: day

Registry last updated2025-08-20

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC)unresolved

Interventions

EnzalutamideDRUG · verified · RxNorm: enzalutamide

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

British Columbia Cancer Agencylead sponsor

Mapped research locations

VancouverBritish Columbia, Canada1 LondonOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04015622 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.